Moleculin Biotech ( ($MBRX) ) has shared an announcement. On December 9, 2025, Moleculin Biotech, Inc. entered into inducement offer agreements ...

Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

Amid a challenging climate for Vancouver’s life sciences sector, Zymeworks Inc. (Nasdaq:ZYME) stands out as a success story ...

Boqii shares surged in after-hours trading following the announcement of a $1.76 million equity repurchase by the founders of ...

EST Moleculin Biotech (MBRX) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving ...

Argenica Therapeutics shares have surged higher after positive clinical trial results for its stroke treatment drug.

(RTTNews) - Biotech and healthcare stocks saw notable activity in Friday's after-hours trading session, with several names posting sharp moves on the back of corporate updates and investor ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that it filed an amendment to its amended and restated certificate of ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...